SAFETY DATA SHEET

SECTION 1 : IDENTIFICATION

Product Name:	**Heparin Sodium in 0.9% Sodium Chloride Injection**
Synonyms:	Heparin Sodium in 0.9% Sodium Chloride Injection (freeflex®); Heparin Sodium in 0.9% Sodium Chloride Injection, 2 USP Units/mL, 500 mL and 1,000 mL (freeflex® bags); Heparin Sodium in 0.9% Sodium Chloride Injection, 2 USP Units/mL, 500 mL and 1,000 mL (freeflex®)
Distributor Name:	Fresenius Kabi USA, LLC
Address:	Three Corporate Drive Lake Zurich, Illinois 60047
General Phone Number:	(847) 550-2300
Customer Service Phone Number:	(888) 386-1300
Health Issues Information:	(800) 551-7176
SDS Creation Date:	March 01, 2021
SDS Revision Date:	March 06, 2024

SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Class: Not classified

Heparin Sodium

Emergency Overview:	This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.
Route of Exposure:	Inhalation Ingestion Eye contact Skin Absorption. Injection.
Eye:	Contact with eyes may cause irritation.
Skin:	May cause skin irritation.
Inhalation:	May cause irritation of respiratory tract.
Ingestion:	May cause irritation.
Signs/Symptoms:	Adverse reactions from prescribed doses include: hemorrhage, local irritation, erythema, mild pain, hematoma, ulceration, hypersensitivity reactions (chills, fever, urticaria), asthma, rhinitis, lacrimation, headache, nausea, vomiting, anaphylactic reactions including shock, itching, burning, and thrombocytopenia. The chief sign of heparin overdose is bleeding (nosebleeds, blood in urine, tarry stools, easy bruising, or petechial formations). When clinical circumstances require reversal of heparinization, protamine sulfate should be administered. Occupational exposure has not been fully investigated.
Aggravation of Pre-Existing Conditions:	Individuals with documented hypersensitivity to heparin sodium and individuals with thrombocytopenia or increased risk for hemorrhage.

SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Citric Acid, Anhydrous	77-92-9	0.37 mg/mL (0.037%) by weight	
Heparin Sodium	9041-08-1	2 USP Units/mL (1,000 Units/500 mL; 2,000 Units/1,000 mL) by weight	
Dibasic Sodium Phosphate Heptahydrate	7782-85-6	4.3 mg/mL (0.43%) by weight	
Sodium Chloride	7647-14-5	9.0 mg/mL (0.9%) by weight	
Water for Injection	7732-18-5	QS (Quantity Sufficient) by weight	

SECTION 4 : FIRST AID MEASURES

Eye Contact:	Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.
Skin Contact:	Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.
Inhalation:	If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.
Ingestion:	If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.
Other First Aid:	For Adverse Event Information, please call (800) 551-7176.

SECTION 5 : FIRE FIGHTING MEASURES

Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.
Lower Flammable/Explosive Limit:	Not established.
Upper Flammable/Explosive Limit:	Not established.
Fire Fighting Instructions:	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
Extinguishing Media:	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Protective Equipment:	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
Hazardous Combustion Byproducts:	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

Personal Precautions:	Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.
Environmental Precautions:	Avoid runoff into storm sewers, ditches, and waterways.
Methods for containment:	Contain spills with an inert absorbent material such as soil, sand or oil dry.
Methods for cleanup:	Absorb spill with inert material (e,g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

Handling:	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
Storage:	Store at 20 to 25 ºC (68 to 77 ºF) [See USP Controlled Room Temperature]. Avoid excessive heat. Do not freeze.
Work Practices:	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Hygiene Practices:	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls:	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
Eye/Face Protection:	Chemical splash goggles. Wear a face shield also when splash hazard exist.
Skin Protection Description:	Protective laboratory coat, apron, or disposable garment recommended.
Hand Protection Description:	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.
Respiratory Protection:	No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective:	Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

Physical State:	Liquid solution.
Color:	Clear and colorless
Boiling Point:	Not established.
Melting Point:	Not established.
Solubility:	Soluble. in water.
Vapor Density:	Not established.
Vapor Pressure:	Not established.
Percent Volatile:	Not established.
pH:	5.0 - 7.5
Molecular Formula:	Mixture
Molecular Weight:	Variable.
Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.

SECTION 10 : STABILITY and REACTIVITY

Chemical Stability:	Stable under normal temperatures and pressures.
Hazardous Polymerization:	Not reported.
Conditions to Avoid:	Protect from freezing.

SECTION 11 : TOXICOLOGICAL INFORMATION

Heparin Sodium :

Acute Toxicity:	LD50: IV Rat 2449 mg/kg LD50: IV Mouse 2800 mg/kg

Citric Acid, Anhydrous :

RTECS Number:	GE7350000

Heparin Sodium :

RTECS Number:	MI0850000
Ingestion:	Oral - Rat LD50: >779000 iu/kg [Details of toxic effects not reported other than lethal dose value] Oral - Mouse LD50: >5 gm/kg [Details of toxic effects not reported other than lethal dose value]
Other Toxicological Information:	Intravenous. - Rat LD50: 391821 iu/kg [Details of toxic effects not reported other than lethal dose value] Intravenous. - Mouse LD50: 2800 mg/kg [Behavioral - convulsions or effect on seizure threshold] Intravenous. - Rat TDLo: 300 units/kg [Blood - hemorrhage Blood - change in clotting factors] Intravenous. - Guinea pig TDLo: 160 units/kg [Blood - change in clotting factors] Intravenous. - Rat TDLo: 84 ku/kg/28D (intermittent) [Musculoskeletal - other changes Nutritional and Gross Metabolic - changes in calcium Nutritional and Gross Metabolic - changes in phosphorus] Subcutaneous - Rat LD50: 46715 iu/kg [Details of toxic effects not reported other than lethal dose value] Subcutaneous - Mouse LD50: >2500 mg/kg [Details of toxic effects not reported other than lethal dose value] Subcutaneous - Human TDLo: 3600 units/kg/18D (intermittent) [Blood - hemorrhage Related to Chronic Data - death] Intraperitoneal. - Mouse LD50: >2500 mg/kg [Details of toxic effects not reported other than lethal dose value]

Dibasic Sodium Phosphate Heptahydrate :

Ingestion:	Oral - Mouse LD50: 6332 mg/kg [Details of toxic effects not reported other than lethal dose value]
Other Toxicological Information:	Subcutaneous - Mouse LD50: 1650 mg/kg [Details of toxic effects not reported other than lethal dose value] Subcutaneous - Mouse TDLo: 51 mg/kg/3D (intermittent) [Related to Chronic Data - changes in uterine weight] Subcutaneous - Rat TDLo: 99 mg/kg/3D (intermittent) [Related to Chronic Data - changes in uterine weight] Subcutaneous - Mouse TDLo: 195 mg/kg/3D (intermittent) [Reproductive - Maternal Effects - uterus, cervix, vagina Related to Chronic Data - changes in uterine weight] Intraperitoneal. - Mouse LD50: 200 mg/kg [Details of toxic effects not reported other than lethal dose value]

Sodium Chloride :

RTECS Number:	VZ4725000
Eye:	Eye - Rabbit Standard Draize test.: 10 mg [Moderate]
Skin:	Administration onto the skin - Rabbit LD50: >10 gm/kg [Details of toxic effects not reported other than lethal dose value] Administration onto the skin - Rabbit Standard Draize test.: 50 mg/24H [mild] Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H [mild]
Inhalation:	Inhalation - Rat LC50: >42 gm/m3/1H [Details of toxic effects not reported other than lethal dose value]
Ingestion:	Oral - Mouse LD50: 4 gm/kg [Details of toxic effects not reported other than lethal dose value] Oral - Rat LD50: 3000 mg/kg [Details of toxic effects not reported other than lethal dose value]
Other Toxicological Information:	Intravenous. - Mouse LD50: 645 mg/kg [Details of toxic effects not reported other than lethal dose value] Intravenous. - Rabbit LDLo: 1100 mg/kg [Behavioral - convulsions or effect on seizure threshold Behavioral - muscle contraction or spasticity Cardiac - other changes] Intravenous. - Guinea pig LDLo: 300 mg/kg [Details of toxic effects not reported other than lethal dose value] Intravenous. - Mouse TDLo: 2.1 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)] Intravenous. - Rabbit LDLo: 1.5 mg/kg [Details of toxic effects not reported other than lethal dose value] Intravenous. - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)] Subcutaneous - Rat LDLo: 3500 mg/kg [Behavioral - irritability] Subcutaneous - Mouse LD50: 3 gm/kg [Details of toxic effects not reported other than lethal dose value] Subcutaneous - Guinea pig LDLo: 2160 mg/kg [Details of toxic effects not reported other than lethal dose value] Subcutaneous - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Skin and Appendages - dermatitis, irritative (after systemic exposure)] Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Effects on Embryo or Fetus - fetal death] Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Specific Developmental Abnormalities - musculoskeletal system] Subcutaneous - Mouse TDLo: 2500 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)] Subcutaneous - Mouse TDLo: 13440 mg/kg [Reproductive - Fertility - abortion] Intraperitoneal. - Mouse LD50: 2602 mg/kg [Details of toxic effects not reported other than lethal dose value] Intraperitoneal. - Rat LD50: 2600 mg/kg [Details of toxic effects not reported other than lethal dose value] Intraperitoneal. - Rat LDLo: 3.72 gm/kg [Behavioral - tremor Behavioral - convulsions or effect on seizure threshold] Intraperitoneal. - Rat TDLo: 1710 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system] Intraperitoneal. - Rat TDLo: 10 gm/kg [Reproductive - Effects on Newborn - behavioral] Intraperitoneal. - Rat Cytogenetic analysis: 2338 mg/kg

SECTION 12 : ECOLOGICAL INFORMATION

SECTION 13 : DISPOSAL CONSIDERATIONS

SECTION 14 : TRANSPORT INFORMATION

DOT Shipping Name:	Not Regulated.
DOT UN Number:	Not Regulated.
IATA Shipping Name:	Non regulated.
IATA UN Number:	Non regulated.
IMDG UN Number :	Non regulated.
IMDG Shipping Name :	Non regulated.

SECTION 15 : REGULATORY INFORMATION

EINECS Number:	201-069-1
Heparin Sodium :	
TSCA Inventory Status:	Listed
Canada DSL:	Listed
Dibasic Sodium Phosphate Heptahydrate :	
TSCA Inventory Status:	Listed
Canada DSL:	Listed
Sodium Chloride :	
TSCA Inventory Status:	Listed
EINECS Number:	231-598-3
Canada DSL:	Listed

SECTION 16 : ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard:	1
HMIS Fire Hazard:	0
HMIS Reactivity:	0
HMIS Personal Protection:	X

SDS Creation Date:	March 01, 2021
SDS Revision Date:	March 06, 2024
SDS Revision Notes:	Overall SDS review - no changes to formulation. Added product name synonym in Section 1 and minorly edited other synonyms used previously.

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2018 Enviance. All Rights Reserved.